Medical Doctor Program year 2025 Source: CMS Open Payments, 2026 publication

Larry Kelly

Pediatrics Pawleys Island, SC Medical Doctor

NPI 1194727628 CMS profile 144939

64 Business Center Dr, Pawleys Island, SC 29585

Open in the dashboard

General payments

$158

4 records reported · program year 2025

Research payments

$0

Paid to them · None reported · program year 2025

Ownership & investment interest

$0

None reported

Through program year 2025, Larry Kelly of Pawleys Island, SC is reported in the CMS Open Payments database as having received $158 across 4 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 45th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

1 row
Year Kind Relative to this record's peak year Amount Records
2025 General $158 4

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Larry Kelly
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Larry Kelly were reported at $158. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Larry Kelly Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $0 $49 $22–$110 $114
2021 $0 $68 $27–$158 $132
2022 $0 $77 $30–$173 $149
2023 $0 $88 $33–$190 $160
2024 $0 $94 $34–$206 $164
2025 $158 $97 $37–$210 $169

Breakdown

Who paid General payments · program year 2025
  1. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $99 1 payment
  2. AbbVie, Inc. $24 1 payment
  3. Dexcom, Inc. $21 1 payment
  4. Novo Nordisk Inc $14 1 payment

Every payment, record by record

What the payments were for General payments · program year 2025
  1. Food and Beverage $158 4 payments
Products named General payments · program year 2025
  1. LifeVest $99 1 payment
  2. UBRELVY $24 1 payment
  3. QULIPTA $24 1 payment
  4. Dexcom G6 Transmitter $21 1 payment
  5. RYBELSUS $14 1 payment
  6. Ozempic $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 113 drugs

Part D claims

6,376

Median for Internal Medicine: 777

Drug cost

$528,241

Median for Internal Medicine: $73,373

Branded share of claims

18.3%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 160 $163,587
Mounjaro Tirzepatide Brand 47 $76,404
Trulicity Dulaglutide Brand 31 $42,583
Ozempic Semaglutide Brand 33 $41,134
Xarelto Rivaroxaban Brand 21 $29,285
Jardiance Empagliflozin Brand 14 $23,883
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 26 $20,884
Entresto Sacubitril/Valsartan Brand 21 $14,252
Farxiga Dapagliflozin Propanediol Brand 17 $12,299
Breo Ellipta Fluticasone/Vilanterol Brand 11 $8,933

The 10 drugs with the highest cost, of 113 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 72 billing codes

Paid by Medicare

$173,998

Of which drugs: $10,617

Medicare patients

1,058

Average age 76

Services billed

4,741

574 women, 484 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 57%
Ischemic heart disease 33%
Diabetes 29%
Atrial fibrillation 26%
Heart failure 25%
Depression 25%
Chronic kidney disease 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 123 125 $8,133

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

4 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record